MedTrace Logo

A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

NCT03825718 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2022-04-28

No results posted yet for this study

Summary

The study is an early, open, single-centered trial.

Conditions

Interventions

BIOLOGICAL

GC007F

GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.

Sponsors & Collaborators

  • Gracell Biotechnology Ltd.

    collaborator OTHER

  • Hebei Yanda Ludaopei Hospital

    lead OTHER

Principal Investigators

  • Peihua Lu, MD/PHD · HeiBei YanDa Ludaopei hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-17
Primary Completion
2020-09-01
Completion
2020-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03825718 on ClinicalTrials.gov